Drugs / LY3509754
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04586920 | Oct 2020 → Oct 2022 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT04152382 | Nov 2019 → Feb 2022 | psoriasis | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3509754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04152382 ↗ |
| Action | Inhibit | “small molecule IL-17A inhibitor LY3509754” PMID 38294091 ↗ Jan 2024 |
| Modality | Small molecule | “Oral Small Molecule Inhibitor of IL-17A” PMID 38294091 ↗ Jan 2024 |
| Route | Oral | “LY3509754 administered orally.” NCT04152382 ↗ |
| Target | IL17A | “small molecule IL-17A inhibitor LY3509754” PMID 38294091 ↗ Jan 2024 |